InveniAI®? LLC announced a strategic collaboration with Ono Pharmaceutical Co. Ltd. (Ono), a renowned pharmaceutical company committed to advancing innovative solutions for unmet medical needs.

InveniAI's cutting-edge technology, including powerful AI and ML algorithms and Generative AI tools, powers its platform AlphaMeld®?, which has consistently demonstrated the ability to unlock transformative therapies by seamlessly integrating complex scientific, medical, chemical, and biological landscapes at unprecedented speed and scale. With AlphaMeld, experts know that all the crucial data points have been considered, enabling rapid prioritization of biological targets and modalities with the most appropriate disease indication(s) while maximizing both safety and efficacy considerations. Ono will conduct validation studies to confirm the hypotheses for multiple therapeutic target candidates identified based on InveniAI's drug discovery hypothees.

Ono will retain exclusive rights to develop and commercialize drug candidates generated through this collaboration worldwide. The collaboration with Ono marks a significant milestone in the pursuit of identifying and accelerating novel drug programs that address diseases with unmet medical needs. InteniAI's AlphaMeld®?

platform has been validated through successful collaborations with leading industry players, including Kyowa Kirin, Shionogi, GSK, Centrexion, and Sosei Heptares. The company's track record includes a drug spinout, Invea Therapeutics Inc.